Trends in United States drug shortages for medications used in gastroenterology



Drug shortages have become more severe in recent years; however, data describing how such shortages impact gastroenterology (GI) drugs are limited. We characterize longitudinal trends of drug shortages in the USA within the scope of GI practice.


Drug shortage data from the University of Utah Drug Information Service were analyzed from January 2001 to December 2014. A board certified gastroenterologist, an internal medicine physician, and a clinical pharmacist identified drug shortages within the scope of GI practice, whether they are used for high-acuity conditions, availability, formulation, or therapeutic category. Trends in the length of shortages for GI drugs were described using standard descriptive statistics and regression analysis.


A total of 1,774 drug shortages were reported over the 14-year period. Of those, 253 shortages (14.3%) were classified within the scope of GI practice. The number of newly-reported GI drug shortages increased from 15 in 2001 to 44 in 2014. The majority of GI drugs (55.7%) were parenteral and 102 shortages (40.3%) were single source drugs. By the end of the study period, 44 (17.4%) GI drugs remained on active shortage with a median duration of 24.3 months (interquartile range [IQR] 6.9-32.1). The median duration for resolved shortages of GI drugs was 7.7 months (IQR 2.9-17.6).


There was a significant increase in shortages of drugs used in GI practice from 2001 to 2014. Many of these drugs were used for high-acuity conditions and alternative agents were also impacted. Gastroenterologists must be cognizant of current shortages in order to mitigate impact on patient care.

Med Access @ point care 2017; 1(1): e58 - e64





Jigar M. Patel, Erin R. Fox, Mark Zocchi, Zone-En Lee, Maryann Mazer-Amirshahi

Article History


Financial support: No grants or funding have been received for this study.
Conflict of interest: None of the authors has financial interest related to this study to disclose.

This article is available as full text PDF.

Download any of the following attachments:


Drug shortages are an important issue in public health and medical care delivery (1). The U.S. Food and Drug Administration (FDA) defines a drug shortage as “a situation in which the total supply of all clinically interchangeable versions of an FDA-regulated drug product is inadequate to meet the projected demand at the user level” (2). For this study, we used the American Society of Health-System Pharmacists (ASHP) definition which describes a drug shortage as “a supply issue that affects how the pharmacy prepares or dispenses a drug product or influences patient care when prescribers must use an alternative agent” (3). In recent years, there have been dramatic increases in drug shortages. In 2005, the FDA’s Drug Shortage Program (DSP) reported shortages of 61 medications and this number increased more than fourfold, to 251 medications by 2011 (4). Although that number significantly decreased to 117 shortages in 2012, 44 new shortages in 2013, and 44 new shortages in 2014, shortages continue to pose a real challenge to public health (4).

There are several reasons for drug shortages, including manufacturer mergers, facility consolidation, manufacturing quality issues, and narrow profit margins for generic drugs (5). Shortages have the potential to impact patient care in a variety of ways and have been associated with treatment delays, lack of treatment when indicated, medication errors, and even patient deaths. In a 2010 hospital survey, 89% of the responding hospitals reported drug shortages that may have caused a medication safety issue or an error in patient care (6). In addition, shortages increase the cost of patient care.

Shortages have been described in the literature for other specialties, such as infectious disease (7) and acute care medications (8); however, there are limited data describing how shortages impact gastroenterology (GI) drugs. In this study, we characterize longitudinal trends in USA drug shortages within the scope of GI practice from 2001 to 2014.


The University of Utah Drug Information Service (UUDIS) has been collecting drug shortage data since January 2001 and publishes critical drug shortage information on a public website ( hosted by the American Society of Health-System Pharmacists (ASHP). The UUDIS implements the ASHP definition of a drug shortage, which differs slightly from, but is more inclusive than, the FDA definition of a shortage. For example, a shortage of prefilled syringes of a specific product may cause significant logistic and safety issues, even if the same medication is available in vials (8). The Government Accountability Office (GAO) used UUDIS data for both reports published on drug shortages (9, 10). The GAO considers these data to be the most comprehensive and reliable source of drug shortage information (9). Detailed methods have been previously published (11) Briefly, UUDIS receives voluntary reports of drug shortages via the reporting feature on the ASHP website. Clinical pharmacists at UUDIS research each shortage reported to verify if a shortage actually exists. This research includes determining all potential manufacturers of a reported drug shortage and all drug presentation codes (National Drug Codes [NDC]). Next, each manufacturer is contacted to determine which NDC codes are in shortage at the national level. The manufacturers are also asked for a reason for the shortage as well as an estimated release date. If most manufacturers are having a national shortage, then UUDIS will post information at the ASHP drug shortage website, noting which products are affected, which products are available, and any specific methods for accessing the product, the reasons for the drug shortage, the estimated resupply dates, and if applicable, implications for patient care, safety concerns, alternatives, and management strategies. UUDIS considers a shortage to be resolved when all suppliers have all presentations available or have discontinued their products. UUDIS also follows the FDA’s drug shortage website, and will generally resolve shortages when the FDA considers the shortages resolved.

UUDIS collects the following drug shortage data using Microsoft® Excel 2007; the generic product name, the therapeutic category, the date the shortage began (date UUDIS was notified), the resolved date, the duration, the reason for the shortage, the controlled substance schedule (if applicable), and whether or not the drug is an injectable product. Drug shortages that occur due to a product discontinuation or withdrawal from the market have the same start and stop date for a duration of zero days (9).

The data set was restricted to shortages that occurred between January 1, 2001 and December 31, 2014. A board certified gastroenterologist, an internal medicine physician, and a clinical pharmacist identified drug shortages within the scope of GI practice. All discrepancies were discussed until a consensus was reached. High-acuity conditions were either life threatening or severe enough requiring immediate intervention, such as GI bleeding and infections. We then categorized the included medications according to whether they are used for high-acuity conditions, marketing status (brand vs. generic), formulation (parenteral vs. other routes of administration), and if the drug is a single-source product (produced by a single manufacturer). We also determined the number of times a medication had been in short supply as well as the availability of a substitute therapy and whether the alternative was also affected by a shortage at any time during the study period. For some portions of the analysis, products were grouped together based on therapeutic category. Trends in the length of shortages for GI drugs were described using standard descriptive statistics and regression analysis. Discontinued products were not included in the analyses of shortage time. A p value of <0.05 was considered significant. Data were analyzed using Stata 13.1 (College Station). The data do not meet the definition of human subjects’ research, and therefore were exempt from Institutional Review Board review. A comprehensive list of products affected by shortages is provided in a supplemental appendix (available online as supplementary material at


Number and duration of shortages

There were 1,774 drug shortages reported over the 14-year study period. Of those, 253 shortages (14.3%) were classified as being within the scope of GI practice. The number of reported GI drug shortages increased from 15 in 2001 to 44 for the year 2014, peaking in 2012 at 46 (Fig. 1). The average number of new shortages reported annually was 18.1 (95% confidence interval [CI], 13.8%-22.3%). Overall median shortage duration was 8.2 months (interquartile range [IQR] 3.1-21.9). By the end of the study period, 44 (17.4%) GI drugs remained on active shortage and 209 (82.6%) had been resolved. Median shortage duration was 24.3 months (IQR 6.9-32.1) for active shortages and 7.7 months (IQR 2.9-17.6) for resolved shortages. There were 53 drugs that were impacted by multiple shortages during the study period. The drug with the largest number of repeated shortages was the Meropenem injection, with a total of 8 shortages over the study period. Among shortages resolved during the study period, the longest single shortage duration was for the hepatitis A vaccine, which was on shortage from August 2, 2007 to April 8, 2013 (2,076 shortage days). Among active drug shortages, the longest single shortage duration was for the ondansetron injection, which has had multiple formulations on shortage since October 21, 2008 (2,262 shortage days as of December 31, 2014).

Number of reported gastrointestinal drug shortages by year.

Types of medications impacted

Of all GI drug shortages, 56 (22.1%) were for drugs used for high-acuity conditions. The majority of GI drugs (55.7%) were parenteral products. Generic drugs were impacted more by shortages (65.2%), and 102 shortages (40.3%) were single-source drugs. Median shortage duration for nonparenteral products was 7.2 months (IQR 2.4-15.6) compared to 9.6 months (IQR 4.1-26.8) for parental products with a Hodges-Lehmann median difference (12) of 2.8 months (95% CI, 0.6%-5.4%). Generic drugs had a median shortage duration of 10.5 months (IQR 4.8-25.0) compared to 5.5 months (IQR 1.4-14.0) for brand-name drugs with a Hodges-Lehmann median difference of 3.9 months (95% CI, 1.8%-6.5%). Single-source drugs had a median shortage duration of 5.3 months (IQR 1.3-11.9) compared to 11.6 months for drugs that were not from a single source (IQR 5.1-27.3), with a Hodges-Lehmann median difference of 5.6 months (95% CI, 3.3%-8.0%). Shortage duration for high-acuity drugs did not significantly differ from nonhigh-acuity drugs.

Almost all (92.1%) of the GI drugs impacted by shortages had a therapeutic alternative, but more than one-third of these alternatives (34.0%) were also impacted by shortage at some point during the study period (Tab. I). For drug shortages where an alternative was also impacted, the median shortage duration was 12.4 months (IQR 7.9-26.9) compared to 6.8 months for drugs without an impacted alternative (IQR 2.7-17.6), with a Hodges-Lehmann median difference of 5.6 months (95% CI, 2.4%-8.3%). The shortage duration for drug shortages with no alternative did not significantly differ from drugs shortages with a therapeutic alternative.

High acuity drugs without alternative or alternatives also impacted

Type of medication Number of shortages Total months on shortage Percentage of study period on shortage
No alternative
 Phytonadione injection 3 27.4 16.3%
 Phytonadione 2 16.5 9.8%
 Thiamine injection 4 40.5 24.1%
 Thiamine 1 1.6 1.0%
Alternative also impacted
 Acyclovir injection 2 35.2 20.9%
 Ceftriaxone injection 1 10.2 6.1%
 Ciprofloxacin 1 13.4 8.0%
 Ciprofloxacin injection 1 55.0 32.8%
 Clindamycin Injection 1 28.3 16.9%
 Ganciclovir injection 1 42.1 25.1%
 Imipenem-cilastatin 2 16.5 9.8%
 Lactated Ringe’s solution 2 11.2 6.6%
 Lansoprazole injection 1 18.0 10.7%
 Linezolid 1 1.8 1.1%
 Meropenem injection 8 50.1 29.8%
 Metronidazole injection 2 49.6 29.5%
 Pantoprazole injection 1 3.1 1.8%
 Piperacillin/Tazobactam injection 4 67.0 39.9%
 Vancomycin 2 81.7 48.7%
 Vancomycin injection 1 13.3 7.9%

Infectious disease drugs were the most common GI drugs on shortage, with 53 (20.9%) drug shortages totaling 790.3 months (65.9 years) during the study period, and a median duration of 10.3 months (IQR 3.8-25.1). Other commonly impacted classes of medications included those used to treat motility disorders, inflammatory bowel disease, and acid suppression, and drugs used for diagnostic and endoscopic procedures (Tab. II).

Types of gastroenterology drugs affected by shortages

Therapeutic category Number of shortages Percentage of shortages Total shortage months Median shortage months (IQR)
IQR = interquartile range.
Acid suppressants 28 11.1% 296.0 5.5 (2.4-18.1)
Analgesic 4 1.6% 129.6 31.0 (19.5-45.3)
Antidote 6 2.4% 44.5 6.5 (0.9-10.5)
Antiemetic 16 6.3% 248.9 11.6 (1.0-23.7)
Contrast agent 4 1.6% 44.3 6.6 (3.4-18.7)
Fluids, electrolytes, nutrition 15 5.9% 88.6 3.6 (1.3-8.2)
Infectious disease 53 20.9% 838.1 10.3 (3.8-25.1)
Inflammatory bowel disease 33 13% 549.9 9.4 (3.6-30.6)
Irritable bowel syndrome 10 4.0% 93.9 8.0 (3.8-15.6)
Liver 28 11.1% 395.8 5.8 (3.3-23.6)
Motility 35 13.8% 400.7 8.2 (5.7-18.6)
Procedural 21 8.3% 310.8 14.9 (3.0-21.1)

Reasons for shortage

In many cases, the manufacturer did not provide the reason for shortage (n = 121). When a reason was provided, the most common reason for shortage was manufacturing problems (27%) followed by supply/demand (11%), and raw materials (6%). Median shortage duration for manufacturing problems was 11.6 months (IQR 4.9-28.3), supply and demand was 8.6 months (IQR 3.5-18.5), and raw materials was 18.6 months (IQR 2.9-34.2) (Tab. III).

Reasons for gastroenterology drug shortages

Reason for shortage Number of shortages Percentage of shortages Median shortage months
NA = not applicable.
Discontinued drugs not included in shortage month calculations.
Business decision 5 2% 0.5 (0.0-3.9)
Discontinued 12 5% NA
Manufacturing problems 67 26% 11.6 (4.9-28.3)
Natural disaster 3 1% 6.1 (6.1-6.2)
Raw materials 15 6% 18.6 (2.9-34.2)
Regulatory 2 1% 26.4 (3.8-49.0)
Supply/demand 28 11% 8.6 (3.5-18.5)
Unknown 121 48% 7.6 (2.9-15.6)


We found a significant increase in shortages of drugs used in GI practice over the 14-year study period (2001-2014). In addition, several drugs had multiple shortages with long total cumulative durations. Drug shortages have previously been reported to have a significant impact on patient care since they limit the treatment options available to prescribers and patients (13). They also add substantial cost to the healthcare system (13). Our paper stands out in that it highlights drug shortages in GI practice over a long period of time, highlighting a trend of increased drug shortages year after year.

An online survey conducted by the American Society for Gastrointestinal Endoscopy (ASGE) Health and Public Policy Committee showed that a large percentage of GI practices have experienced significant shortages in drugs used for sedation during endoscopic procedures and the management of GI bleeding (14). A survey of American College of Gastroenterology (ACG) members showed that intravenous sedation was administered in 98.2% of esophagogastroduodenoscopies (EGDs) and 98.8% of colonoscopies (15). Approximately three-fourths of those surveyed reported using conventional sedation (a benzodiazepine, e.g., midazolam with an opioid analgesic, e.g., fentanyl) while 25.7% utilized propofol-based sedation (15). We found that drug shortages for midazolam, fentanyl, and propofol, which are the first-line sedatives, existed at some point in time during our study period (Tab. IV). In addition, we found significant drug shortages for second-line sedatives, such as meperidine and ketamine, as well as adjuncts to the benzodiazepine/opioid combination, which include diphenhydramine, promethazine, and droperidol (16).

Medications in short supply used for sedation in gastrointestinal procedures

Product Number of times in short supply Total months short
Fentanyl 2 49
Meperidine 5 56
Midazolam 2 60
Propofol 3 58

In a letter to the FDA, the ACG has also addressed concerns regarding a shortage of sedative drugs used in endoscopy centers and hospitals (17). Such drug shortages have forced practices to cancel procedures, and have increased costs to the healthcare system as gastroenterologists are forced to substitute moderate sedatives with other sedatives, such as propofol, which may require additional training or the presence of an anesthesia professional (17).

In addition, the ASGE guideline for sedation and anesthesia in GI endoscopy mandates that specific antagonists of opioids (naloxone) and benzodiazepines (flumazenil) should be present and readily available in every endoscopy unit. Our study found drug shortages for both naloxone and flumazenil over the years (16). These findings are consistent with ASGE’s Health and Public Policy Committee’s national online survey (14).

Antiinfective agents and drugs used in management of inflammatory bowel disease were the two most impacted groups in this study. Although substitutes are available for most of these agents, it must be highlighted that there was a rising trend in the increase of drug shortages in these categories over the study period, as well as an increased burden of cost to the healthcare system. For example, drug shortages were seen for both metronidazole and oral vancomycin, which are used for the treatment of the Clostridium difficile infection, with the latter being used for severe disease (18, 19). C. difficile caused almost half a million infections in the USA in 2011; an estimated 83,000 of those patients had at least one recurrence; and approximately 29,000 died within 30 days of the initial diagnosis (20). Due the high recurrence rate of up to 25% of cases, it is important to treat this infection for 10-14 days, and compliance is of the utmost importance. Substituting oral metronidazole for newer agents, like fidoxamicin, can increase the cost of treatment from $22 to $2,800 for a 10-day course (19).

We also found significant shortages for parenteral nutrition ingredients and micronutrients. A recent New York Times article highlighted the story of a Cleveland patient with Crohn’s disease who was unaware that zinc had been removed from her daily intravenous (IV) nutrition until she developed side effects from the deficiency (21). In response to this news, Dr. Heller from the Crohn’s & Colitis Foundation of America (CCFA) recommended that doctors keep patients informed of therapy changes and ensure that they are educated and empowered to make the best decisions about their care (22). Most patients want to be informed regarding drug shortages that might affect their care, even if the severity of potential side effects is small (23).

Another category of drug shortage of high importance is that of vaccines. Prevention is better than cure, and this is especially true for vaccine-preventable diseases. There were multiple shortages of both vaccines against hepatitis A and B viruses during the study period. In this study, we found a reported shortage of 50 months for the hepatitis B virus (HBV) vaccine. Hepatitis B vaccination of individuals at a high risk of acquiring the virus, including healthcare workers, is highly recommended as per the Centers for Disease Control and Prevention (CDC) guidelines and has effectively been shown to reduce the incidence of newly infected cases in society (24). During 2000-2004, self-reported hepatitis B vaccination coverage among adults at risk for HBV infection increased from 30% to 45%; this increase in vaccination coverage likely contributed to the 35% decline in acute hepatitis B incidence that occurred during this period (25).

Our study found significant drug shortages for epinephrine and IV proton pump inhibitors (PPIs), which are used for the management of acute GI bleeding, and could be life-saving measures. The combined shortage of IV PPIs was 9 months over the 14-year period. One study found that only 50% of upper GI hemorrhage (UGIH) patients received IV PPI for an appropriate indication, and that only 33% of non-UGIH patients were truly nil by mouth (26). Strict adherence to evidence-based guidelines from professional societies for the use of these agents can reduce unnecessary use, and can help mitigate drug shortages as well as healthcare costs while maintaining the utmost standard of care. Two prospective studies found no acceptable indication for IV PPI in 56% of patients during their hospitalization (27). Newer formulations and drugs can also help reduce drug demand. One such example is the introduction of new oral PPI products that can be administered as a suspension expanded the therapeutic options for critically ill patients (28).

While relatively few in number, shortages of diagnostic agents for GI procedures can post serious problems. For example, shortages of sincalide impacted patient care due to the lack of pharmaceutical alternatives and the potential delay in evaluating gall bladder function. Some clinicians substituted a large amount of fat for sincalide, but this substitute is not appropriate for most patients. Shortages of both indigo carmine as well as methylene blue seriously impacted endoscopic procedures, specifically chromoendoscopy, which aids in the identification of Barrett’s esophagus and the characterization of colonic polyps/dysplasia. A shortage of both dyes at the same time left no alternatives for clinicians.

Physicians should be cognizant of medication errors and adverse drug events, which may occur as a result of shortages. Substituting medications can result in errors as the prescriber and nursing staff may be less familiar with available alternatives, specifically dealing with proper dosing, administration protocols, and contraindications (29). In addition, different strengths or concentrations may be stocked because of limited availability of the product that is usually stocked. In one case, a patient was overdosed with ketamine due to a diluting error, which resulted in confusion and delirium during a GI endoscopic procedure (30). In this situation, a shortage of ketamine in 10 mg/mL strength had resulted in the hospital having to stock the 50 mg/mL concentration in an operating room automated dispensing cabinet. In order to protect the safety of patients, ASGE endorses the CDC’s safe practice guideline, which states that shortages of some essential medications may warrant the implementation of meticulously applied practice and quality standards to subdivide contents of single-dose/single-use vials (31). Another way to prevent such errors is to have regular staff meetings, optimize communication to staff about current shortages, have protocols in place for the use of alternative therapies, and to have staff assigned to monitor medication changes (17).


The major limitation of this study was that we could not assess the actual impact that shortages had on individual institutions or on patient care – either in the form of delayed or suboptimal therapy or in terms of resultant medication errors and adverse outcomes. Also, we could not describe the severity of shortages affecting a particular product (e.g., whether the product was in limited supply or completely unavailable). There were limited data pertaining to the comparative efficacy of some therapeutic alternatives that were identified, and we did not take into account additional costs or toxicity when considering the use of substitutes. The duration of unresolved shortages would have been underestimated using our methodology. Finally, we could not account for the time and resources used by institutions to mitigate drug shortages. These are all potential areas for additional prospective study.


There was a significant number of drug shortages affecting drugs used in gastroenterology during the study period. The shortages were the result of several different factors that affected the manufacturing process and access to these medications. The impact of these shortages has been felt by the medical system as a whole, but further research is needed at the patient-outcome level. Future research should evaluate patient harm and the increase in healthcare costs derived from these shortages. It is the responsibility of everyone involved in the healthcare system – the pharmaceutical industry, the FDA, health care institutions, and clinicians – to identify shortages as quickly as possible and to implement mitigation strategies before they become critical (32).


Financial support: No grants or funding have been received for this study.
Conflict of interest: None of the authors has financial interest related to this study to disclose.
  • 1. Krisl JC Fortier CR Taber DJ Disruptions in the supply of medications used in transplantation: implications and management strategies for the transplant clinician. Am J Transplant 2013 13 1 20 30 Google Scholar
  • 2. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Office of New Drugs, Drug Shortage Management, 2012. Manual of policies and procedures Accessed June 19, 2017. Google Scholar
  • 3. Fox ER Birt A James KB Kokko H Salverson S Soflin DL ASHP Expert Panel on Drug Product Shortages. ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems. Am J Health Syst Pharm 2009 66 15 1399 1406 Google Scholar
  • 4. Department of Health and Human Services Food and Drug Administration. Third Annual Report on Drug Shortages for Calendar Year 2015 Accessed June 19, 2017. Google Scholar
  • 5. Woodcock J Wosinska M Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther 2013 93 2 170 176 Google Scholar
  • 6. Orlovich DS Kelly RJ Drug shortages in the U.S.: a balanced perspective. Accessed June 19, 2017. Google Scholar
  • 7. Quadri F Mazer-Amirshahi M Fox ER et al. Antibacterial drug shortages from 2001 to 2013: implications for clinical practice. Clin Infect Dis 2015 60 12 1737 1742 Google Scholar
  • 8. Hawley KL Mazer-Amirshahi M Zocchi MS Fox ER Pines JM Longitudinal trends in U.S. drug shortages for medications used in emergency departments (2001-2014). Acad Emerg Med 2016 23 1 63 69 Google Scholar
  • 9. United States Government Accountability Office. Drug shortages: public health threat continues, despite efforts to help ensure product availability. Accessed June 19, 2017. Google Scholar
  • 10. United States Government Accountability Office. Drug shortages: FDA’s ability to respond should be strengthened Accessed June 19, 2017. Google Scholar
  • 11. Fox ER Tyler LS Managing drug shortages: seven years experience at one health system. Am J Health Syst Pharm 2003 60 3 245 253 Google Scholar
  • 12. Newson R Parameters behind “nonparametric” statistics: Kendall’ tau, Somers’ D and median differences. Stata J 2002 2 1 45 64 Google Scholar
  • 13. Fox ER Sweet BV Jensen V Drug shortages: a complex health care crisis. Mayo Clin Proc 2014 89 3 361 373 Google Scholar
  • 14. Menees SB Vargo JJ Bonta C Mayo L Jacobson BC Drug shortages in America: what about the gastroenterologist? Gastrointest Endosc 2013 77 4 641 645 Google Scholar
  • 15. Cohen LB Wecsler JS Gaetano JN et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol 2006 101 5 967 974 Google Scholar
  • 16. Cohen LB Delegge MH Aisenberg J et al. AGA Institute. AGA Institute review of endoscopic sedation. Gastroenterology 2007 133 2 675 701 Google Scholar
  • 17. American College of Gastroenterology. Drug shortages in clinical gastroenterology Accessed June 19, 2017. Google Scholar
  • 18. Cohen SH Gerding DN Johnson S et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010 31 5 431 455 Google Scholar
  • 19. Surawicz CM Brandt LJ Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013 108 4 478 498, quiz 499. Google Scholar
  • 20. Lessa FC Mu Y Bamberg WM et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015 372 9 825 834 Google Scholar
  • 21. Fink S Drug shortages forcing hard decisions on rationing treatments. Accessed June 19, 2017. Google Scholar
  • 22. Cision PR Newswire. CCFA: Drug shortages highlight the need for increased patient engagement in care New York. Accessed June 19, 2017. Google Scholar
  • 23. Hsia IK Dexter F Logvinov I Tankosic N Ramakrishna H Brull SJ Survey of the National Drug Shortage Effect on Anesthesia and Patient Safety: A Patient Perspective. Anesth Analg 2015 121 2 502 506 Google Scholar
  • 24. Schillie S Murphy TV Sawyer M et al. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep 2013 62 Rr-10 1 19 Google Scholar
  • 25. Mast EE Weinbaum CM Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006 55 Rr-16 1 33 quiz CE1-4. Google Scholar
  • 26. Kaplan GG Bates D McDonald D Panaccione R Romagnuolo J Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. Clin Gastroenterol Hepatol 2005 3 12 1207 1214 Google Scholar
  • 27. Guda NM Noonan M Kreiner MJ Partington S Vakil N Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol 2004 99 7 1233 1237 Google Scholar
  • 28. Devlin JW Proton pump inhibitors for acid suppression in the intensive care unit: formulary considerations. Am J Health Syst Pharm 2005 62 10 Suppl 2 S24 S30 Google Scholar
  • 29. Mazer-Amirshahi M Pourmand A Singer S Pines JM van den Anker J Critical drug shortages: implications for emergency medicine. Acad Emerg Med 2014 21 6 704 711 Google Scholar
  • 30. Institute for Safe Medication Practices Medication Safety Alert. Drug shortage causes error 2015 12 3 1 3 Accessed June 19, 2017. Google Scholar
  • 31. Centers for Disease Control and Prevention. Protect patients against preventable harm from improper use of single-dose/single-use vials. Accessed June 19, 2017. Google Scholar
  • 32. Jensen V Rappaport BA The reality of drug shortagesthe case of the injectable agent propofol. N Engl J Med 2010 363 9 806 807 Google Scholar



  • Department of Internal Medicine, MedStar Washington Hospital Center, Washington, DC - USA
  • Drug Information Service, University of Utah Health Care, Salt Lake City, Utah - USA
  • Center for Healthcare Innovation and Policy Research, George Washington University School of Medicine and Health Sciences, Washington, DC - USA
  • Department of Gastroenterology, MedStar Georgetown University Hospital, Washington Hospital Center, Washington, DC - USA
  • Department of Emergency Medicine, Georgetown University School of Medicine, MedStar Washington Hospital Center, Washington, DC - USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

This article has supplementary materials available to download.